arrow_back Back to App

Limiting Patent Disputes for Drugs and Biological Products

This new law aims to limit the number of patents pharmaceutical companies can use in lawsuits concerning generic drugs and biosimilar products. This could accelerate the introduction of cheaper drug alternatives to the market, potentially lowering healthcare costs for citizens.
Key points
Pharmaceutical companies will be limited to asserting only one patent per patent group in infringement actions against generic and biosimilar drug manufacturers.
This change applies to new applications for generic and biosimilar drug approvals submitted after the law's enactment.
The goal is to increase competition in the pharmaceutical market, potentially leading to lower drug prices for consumers.
article Official text account_balance Process page
Introduced
Citizen Poll
No votes cast
Additional Information
Print number: 119_HR_3269
Sponsor: Rep. Arrington, Jodey C. [R-TX-19]
Process start date: 2025-05-08
Lustra uses Artificial Intelligence. Verify details in source documents.
Summarized by: gemini-2.5-flash-preview-05-20
Source data: api.congress.gov
AI work logs for this document launch

OFFICIAL LEGAL TITLE

ETHIC Act

FREQUENTLY ASKED QUESTIONS

What is the official ID of this bill?

The official print number for this legislation is 119_HR_3269.

Which chamber initiated this legislation?

This legislation was initiated in the House of Representatives.

When did the legislative process begin?

The process officially started on 2025-05-08.

What are the main provisions?

Key points include:

  • Pharmaceutical companies will be limited to asserting only one patent per patent group in infringement actions against generic and biosimilar drug manufacturers.
  • This change applies to new applications for generic and biosimilar drug approvals submitted after the law's enactment.
  • The goal is to increase competition in the pharmaceutical market, potentially leading to lower drug prices for consumers.
What is the specific legal status?

The current status is Introduced.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Rep. Arrington, Jodey C. [R-TX-19].

What is the latest detailed status?

The latest detailed status is: Referred to the House Committee on the Judiciary.

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-22.

CATEGORIES

Health Courts and Law Economy